These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15106030)

  • 21. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
    Ewing P; Eirefelt SJ; Andersson P; Blomgren A; Ryrfeldt A; Gerde P
    J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):169-80. PubMed ID: 18518793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Nebulised budesonide is effective for severe infantile asthma--a report of two clinical cases].
    Kameda M; Murayama N; Takamatsu I; Inoue T; Doi S; Toyoshima K
    Arerugi; 1999 Apr; 48(4):472-5. PubMed ID: 10355152
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhalation device, pulmonary deposition and clinical effects of inhaled therapy.
    Pauwels R
    J Aerosol Med; 1997; 10 Suppl 1():S17-21. PubMed ID: 10165119
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of equipment dead space and pediatric breathing patterns on inhaled mass of nebulized budesonide.
    Nikander K; Denyer J; Smaldone GC
    J Aerosol Med; 1999; 12(2):67-73. PubMed ID: 10539709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic availability of Rhinocort Aqua (budesonide) nasal spray: importance of formulation and definition of delivered dose.
    O'Dowd L; Thorsson L; Edsbacker S
    J Allergy Clin Immunol; 2002 Jun; 109(6):1037; author reply 1037-8. PubMed ID: 12063539
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effects of inhalation of a glucocorticoid using metered-dose propellant gas aerosol and Turbohaler--a roentgen pilot study].
    Vogel H; Wettmarshausen C
    Pneumologie; 1995 Oct; 49(10):559-60. PubMed ID: 8584527
    [No Abstract]   [Full Text] [Related]  

  • 27. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device.
    Fyrnys B; Stang N; Wolf-Heuss E
    Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S7-11. PubMed ID: 11385814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The science of nebulised drug delivery.
    O'Callaghan C; Barry PW
    Thorax; 1997 Apr; 52 Suppl 2(Suppl 2):S31-44. PubMed ID: 9155849
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma.
    Shrewsbury SB; Bosco AP; Uster PS
    Int J Pharm; 2009 Jan; 365(1-2):12-7. PubMed ID: 18786624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
    Bur M; Huwer H; Muys L; Lehr CM
    J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budesonide and risk of pneumonia.
    Black PN; Sexton PM
    Lancet; 2009 Dec; 374(9707):2050-2051. PubMed ID: 20109825
    [No Abstract]   [Full Text] [Related]  

  • 32. Lung deposition of inhaled drugs increases with age.
    Onhøj J; Thorsson L; Bisgaard H
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1819-22. PubMed ID: 11069819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalers.
    Persson G; Ankerst J; Gillen M; Bengtsson T; Thorsson L
    Curr Med Res Opin; 2008 May; 24(5):1511-7. PubMed ID: 18419877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
    Pitcairn G; Reader S; Pavia D; Newman S
    J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacological and clinical profile of Budesonide inhalation suspension (Pulmicort inhalation liquid), an inhaled steroid drug for asthma].
    Watanabe H; Yano S; Kageyama A
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):197-207. PubMed ID: 17379972
    [No Abstract]   [Full Text] [Related]  

  • 36. Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
    Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R
    Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide suspension for infants and young children with persistant asthma.
    Lipworth BJ; Jackson CM
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1277-8. PubMed ID: 11316669
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhaler and spacer use in obstructive airway diseases.
    Jones MD; Yeager H
    Am Fam Physician; 1990 Oct; 42(4):1007-13. PubMed ID: 2220509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease.
    Centanni S; Di Marco F
    Expert Opin Pharmacother; 2005 Nov; 6(14):2525-34. PubMed ID: 16259583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.